Evidence map›Paper›PMID 33248139›Full record

ArticleUrology2021

Effect of Continued Perioperative Anticoagulant Therapy on Bleeding Outcomes Following Robot-assisted Radical Prostatectomy.

Masashi Kubota, Takashi Matsuoka, Toshinari Yamasaki, Hidetoshi Kokubun, Hiroki Hagimoto, Shiori Murata, Noriyuki Makita, Issei Suzuki, Yohei Abe, Yoichiro Tohi and 3 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. A systematic review and meta-analysis of unplanned hospital visits and re-admissions following radical prostatectomy for prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Masashi KubotaDepartment of Urology, Kobe City Medical Centre General Hospital, Kobe, Japan. Electronic address: maskubo@kuhp.kyoto-u.ac.jp.
Takashi MatsuokaDepartment of Urology, Kobe City Medical Centre General Hospital, Kobe, Japan.
Toshinari YamasakiDepartment of Urology, Kobe City Medical Centre General Hospital, Kobe, Japan.
Hidetoshi KokubunDepartment of Urology, Kobe City Medical Centre General Hospital, Kobe, Japan.
Hiroki HagimotoDepartment of Urology, Kobe City Medical Centre General Hospital, Kobe, Japan.
Shiori MurataDepartment of Urology, Kobe City Medical Centre General Hospital, Kobe, Japan.
Noriyuki MakitaDepartment of Urology, Kobe City Medical Centre General Hospital, Kobe, Japan.
Issei SuzukiDepartment of Urology, Kobe City Medical Centre General Hospital, Kobe, Japan.
Yohei AbeDepartment of Urology, Kobe City Medical Centre General Hospital, Kobe, Japan.
Yoichiro TohiDepartment of Urology, Kobe City Medical Centre General Hospital, Kobe, Japan.
Naofumi TsutsumiDepartment of Urology, Kobe City Medical Centre General Hospital, Kobe, Japan.
Koji InoueDepartment of Urology, Kobe City Medical Centre General Hospital, Kobe, Japan.
Mutsushi KawakitaDepartment of Urology, Kobe City Medical Centre General Hospital, Kobe, Japan.
Kobe City Medical Center General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the impact of continued perioperative anticoagulant drug administration on bleeding and complications in patients undergoing robot-assisted radical prostatectomy.

methodsBetween January 2014 and January 2020, 620 patients with prostate cancer underwent robot-assisted radical prostatectomies and were retrospectively reviewed. Fourteen patients who discontinued antithrombotic therapy were excluded. Among the 606 included patients, 31 continued anticoagulant therapy during the perioperative phase (anticoagulant group). The anticoagulant group outcomes were compared with those of patients who continued clopidogrel and prasugrel (thienopyridine group = 13), aspirin monotherapy (aspirin group = 61), and no chronic antithrombotic agent (control group = 501). The primary outcome was the incidence of bleeding complications requiring transfusion, additional intervention, or readmission. Secondary outcomes were the incidence of thrombotic complications, estimated blood loss, and overall complication rates.

resultsAmong the 31 patients in the anticoagulant group, 20 (65%) used directed oral anticoagulants, 11 (35%) used warfarin, and 5 used combined aspirin. Only 1 (3%) patient in the anticoagulant group required postoperative transfusion, and none required additional interventions or readmission. No significant differences were detected between the anticoagulant and other groups (anticoagulant vs thienopyridine, aspirin, and control groups) regarding bleeding complications (3% vs 8%, P = .51; 0%, P = .34; 0.4%, P = .17, respectively), thrombotic complications (3% vs 0%, P = .70; 2%, P = .56; 0.2%, P = .11, respectively), estimated blood loss (200 vs 100 mL, P = .63; 175 mL, P = .64; 165 mL, P = .74, respectively), or other high-grade complications (6% vs 0%, P = .49; 2%, P = .26; 3%, P = .24, respectively).

conclusionPerioperative continuation of anticoagulant use is feasible for patients undergoing robot-assisted radical prostatectomy.

Indexed as

ProstatectomyRobotic Surgical ProceduresAgedAnticoagulantsAntithrombinsAspirinBlood TransfusionClopidogrelContinuity of Patient CareHumansIncidenceMalePerioperative CarePlatelet Aggregation InhibitorsPostoperative HemorrhagePrasugrel HydrochlorideAnticoagulantsAntithrombinsAspirinClopidogrelPlatelet Aggregation InhibitorsPrasugrel HydrochlorideWarfarin

Identifiers

PMID33248139
OpenAlexW3108497918

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.